New CAR-T therapy takes on tough blood cancers
NCT ID NCT07312630
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new cell therapy called LV009 for people with certain blood cancers (lymphoma and leukemia) that have come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to target cancer cells. The main goal is to check safety and how the therapy behaves in the body, with only 19 participants enrolled so far.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LV009 injection (a type of CAR-T cell therapy)
What this could lead to
If it works, this could point toward a new treatment option for people with certain blood cancers that have not responded to standard therapies.
What could go wrong
This is a very early, small trial (19 people) focused on safety and dosing. It may not show strong effectiveness, and there are risks of serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
PersonGen.Anke Cellular Therapeutice Co., Ltd.
RECRUITINGHefei, Anhui, 230088, China
Contact Phone: •••-•••-•••• Email: •••••@•••••